Form 4: CRISPR Therapeutics CEO Samarth Kulkarni Reports Stock Transactions

Sentiment:

SEC Form 4


CEO Samarth Kulkarni reports acquisition and disposal of CRISPR Therapeutics shares related to vesting of restricted stock units and tax obligations.

Summary

  • Samarth Kulkarni, CEO of CRISPR Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
  • On March 10, 2025, Kulkarni acquired 19,250 common shares through the vesting of restricted stock units.
  • On March 11, 2025, Kulkarni sold 9,973 shares at $42.42 to cover tax withholding obligations.
  • Also on March 11, 2025, Kulkarni acquired 9,000 common shares through the vesting of restricted stock units.
  • On March 12, 2025, Kulkarni sold 4,462 shares at $43.32 to cover tax withholding obligations.
  • Following these transactions, Kulkarni directly owns 185,428 common shares and indirectly owns 85,622 shares through The Kulkarni 2023 GRAT.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by the CEO, with no inherent positive or negative sentiment.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Stakeholder Impact

  • The transactions provide transparency to shareholders regarding insider activity.

Key Dates

DateDescription
03/10/2023Restricted stock unit award granted with respect to 77,000 Common Shares.
03/11/2021Restricted stock unit award granted with respect to 36,000 Common Shares.
03/10/2024One quarter of the 77,000 shares granted on 03/10/2023 vesting date.
03/11/2022One quarter of the 36,000 shares granted on 03/11/2021 vesting date.
03/11/2023One quarter of the 36,000 shares granted on 03/11/2021 vesting date.
03/10/2025Acquisition of 19,250 shares due to RSU vesting; one quarter of the 77,000 shares granted on 03/10/2023 vesting date.
03/11/2024One quarter of the 36,000 shares granted on 03/11/2021 vesting date.
03/11/2025Sale of 9,973 shares at $42.42; Acquisition of 9,000 shares due to RSU vesting; one quarter of the 36,000 shares granted on 03/11/2021 vesting date.
03/12/2025Sale of 4,462 shares at $43.32.
03/10/2026One quarter of the 77,000 shares granted on 03/10/2023 vesting date.
03/10/2027One quarter of the 77,000 shares granted on 03/10/2023 vesting date.

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.